MET and lung carcinoma: Additionally, since we previously demonstrated that the Hsp90 inhibitor overcame EGFR-TKI resistance triggered by HGF, a ligand of MET, in EGFR-mutant lung cancer cells [21], we determined whether Hsp90 inhibition by 17-DMAG would overcome ligand-triggered alectinib resistance in ALK-rearranged NSCLC cells.